Mingde Biotechnology: Announcement on the progress of major asset restructuring
Securities code: 002932 Securities abbreviation: Mingde Biotechnology Announcement number: 2026-015 Wuhan Mingde Biotechnology Co., Ltd.
Announcement on the progress of major asset restructuring
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Special tips:
Wuhan Mingde Biotechnology Co., Ltd. (hereinafter referred to as the "Company") disclosed the "Informative Announcement on the Planning of Major Asset Reorganization and the Signing of the Equity Acquisition Intention Agreement" (Announcement Number: 2025-056) on December 31, 2025, and has explained the relevant matters involved in this transaction.
The work related to this transaction is being actively promoted, and the parties to the transaction have not yet signed a formal agreement. There is still great uncertainty in this transaction. The company will fulfill its information disclosure obligations in stages and in a timely manner based on the progress of relevant matters. Investors are kindly requested to pay attention to the company's subsequent announcements and pay attention to investment risks.
1. Transaction Overview
The company plans to acquire 100% equity of Wuhan Bikel Rescue Supplies Co., Ltd. (hereinafter referred to as the "Target Company") held by Lanfan Medical Co., Ltd. in cash. After the completion of this transaction, the target company will become a wholly-owned subsidiary of the company. This transaction is expected to constitute a major asset reorganization stipulated in the "Administrative Measures for Major Asset Reorganization of Listed Companies". This transaction is planned to be in cash and does not constitute a restructuring and listing, nor does it involve the issuance of shares by the listed company. This transaction does not constitute a related transaction, nor will it lead to changes in the listed company's controlling shareholders and actual controllers.
2. Historical disclosure of this transaction
The company disclosed the "Informative Announcement on Planning for Major Asset Reorganization and Signing of the Equity Acquisition Intention Agreement" on December 31, 2025 (Announcement Number: 2025-056).
The company disclosed the "Announcement on the Progress of Major Asset Reorganization" on January 30, 2026 (Announcement No.: 2026-005).
The company disclosed the "Announcement on the Progress of Major Asset Reorganization" on February 28, 2026 (Announcement No.: 2026-009).
3. Progress of this transaction
As of the date of this announcement, the company has continued to communicate and negotiate with all relevant parties regarding this transaction, and actively promotes auditing, evaluation, due diligence and other related work. The relevant parties of this transaction have not yet signed the formal transaction documents. The company will perform the relevant decision-making approval procedures and information disclosure obligations in strict accordance with the relevant laws and regulations based on the progress of this transaction.
4. Risk warning
As of the date of this announcement, work related to this transaction is being actively promoted, the specific transaction plan is still under discussion, and the parties to the transaction have not yet signed a formal agreement. There is still great uncertainty in this transaction. The company will fulfill its information disclosure obligations in stages and in a timely manner based on the progress of relevant matters. Investors are kindly requested to pay attention to the company's subsequent announcements and pay attention to investment risks.
Announcement is hereby made.
Wuhan Mingde Biotechnology Co., Ltd.
board of directors
March 30, 2026